

1

2 **Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England:**  
3 **cohort study in OpenSAFELY using linked primary care, secondary care and death registration data**

4

5 Krishnan Bhaskaran PhD<sup>1\*</sup> (corresponding: [krishnan.bhaskaran@lshtm.ac.uk](mailto:krishnan.bhaskaran@lshtm.ac.uk)), Christopher T Rentsch  
6 PhD<sup>1\*</sup>, George Hickman BEng<sup>2\*</sup>, William J Hulme PhD<sup>2\*</sup>, Anna Schultze PhD<sup>1</sup>, Helen J Curtis DPhil<sup>2</sup>,  
7 Kevin Wing PhD<sup>1</sup>, Charlotte Warren-Gash PhD<sup>1</sup>, Laurie Tomlinson PhD<sup>1</sup>, Chris J Bates PhD<sup>3</sup>, Rohini  
8 Mathur PhD<sup>1</sup>, Brian MacKenna MPharm<sup>2</sup>, Viyaasan Mahalingasivam MRCP<sup>1</sup>, Angel Wong PhD<sup>1</sup>, Alex J  
9 Walker PhD<sup>2</sup>, Caroline E Morton MRCP<sup>2</sup>, Daniel Grint PhD<sup>1</sup>, Amir Mehrkar MRCP<sup>2</sup>, Rosalind M  
10 Eggo PhD<sup>1</sup>, Peter Inglesby MPhil<sup>2</sup>, Ian J Douglas PhD<sup>1</sup>, Helen I McDonald PhD<sup>1</sup>, Jonathan Cockburn  
11 BSc<sup>3</sup>, Elizabeth J Williamson PhD<sup>1</sup>, David Evans MPhil<sup>2</sup>, John Parry MRCP<sup>3</sup>, Frank Hester BSc<sup>3</sup>, Sam  
12 Harper MSc<sup>3</sup>, Stephen JW Evans MSc<sup>1</sup>, Sebastian Bacon BA<sup>2</sup>, Liam Smeeth PhD<sup>1+</sup>, Ben Goldacre  
13 MRCPsych<sup>2+</sup> (\* = contributed equally; + = joint senior authors)

14 *1 – Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine;*  
15 *2 - The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford,*  
16 *UK; 3 – The Phoenix Partnership, TPP House, Horsforth, Leeds, UK*

17

18 **ABSTRACT**

19 **Background:** There is concern about medium to long-term adverse outcomes following acute  
20 COVID-19, but little relevant evidence exists. We aimed to investigate whether risks of hospital  
21 admission and death, overall and by specific cause, are raised following discharge from a COVID-19  
22 hospitalisation.

23 **Methods and Findings:** Working on behalf of NHS-England, we used linked primary care and hospital  
24 data in OpenSAFELY to compare risks of hospital admission and death, overall and by specific cause,  
25 between people discharged from COVID-19 hospitalisation (February-December 2020), and (i)  
26 demographically-matched controls from the 2019 general population; (ii) people discharged from  
27 influenza hospitalisation in 2017-19. We used Cox regression adjusted for personal and clinical  
28 characteristics.

29 24,673 post-discharge COVID-19 patients, 123,362 general population controls, and 16,058 influenza  
30 controls were followed for  $\leq 315$  days. Overall risk of hospitalisation or death (30968 events) was  
31 higher in the COVID-19 group than general population controls (adjusted-HR 2.23, 2.14-2.31) but  
32 similar to the influenza group (adjusted-HR 0.94, 0.91-0.98). All-cause mortality (7439 events) was  
33 highest in the COVID-19 group (adjusted-HR 4.97, 4.58-5.40 vs general population controls and 1.73,  
34 1.60-1.87 vs influenza controls). Risks for cause-specific outcomes were higher in COVID-19 survivors  
35 than general population controls, and largely comparable between COVID-19 and influenza patients.  
36 However, COVID-19 patients were more likely than influenza patients to be readmitted/die due to  
37 their initial infection/other lower respiratory tract infection (adjusted-HR 1.37, 1.22-1.54), and to  
38 experience mental health or cognitive-related admission/death (adjusted-HR 1.36, 1.01-2.83); in  
39 particular, COVID-19 survivors with pre-existing dementia had higher risk of dementia death. One  
40 limitation of our study is that reasons for hospitalisation/death may have been misclassified in some  
41 cases due to inconsistent use of codes.

42 **Conclusions:** People discharged from a COVID-19 hospital admission had markedly higher risks for  
43 rehospitalisation and death than the general population, suggesting a substantial extra burden on  
44 healthcare. Most risks were similar to those observed after influenza hospitalisations; but COVID-19  
45 patients had higher risks of all-cause mortality, readmissions/death due to the initial infection, and  
46 dementia death, highlighting the importance of post-discharge monitoring.

47

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

48

## 49 Introduction

50 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in early 2020 and rapidly  
51 spread around the world, infecting >140 million people globally.<sup>1</sup> Acute infection can be  
52 asymptomatic or mild,<sup>2</sup> but a substantial minority of infected people experience severe COVID-19  
53 requiring hospitalisation,<sup>3</sup> with age being a major risk factor, along with male sex, non-White  
54 ethnicity and certain comorbidities.<sup>4-6</sup> Early in the pandemic, the proportion surviving hospitalisation  
55 was around 50-70%,<sup>7</sup> though improved treatment guidelines and the identification of effective  
56 therapies such as dexamethasone helped to improve survival rates.<sup>8,9</sup> There is now a large and  
57 growing population of people who have survived a COVID-19 hospitalisation, but little is known  
58 about their longer-term health outcomes.

59 Emerging evidence suggests that a subset of people infected with SARS-CoV-2 can experience health  
60 problems for at least several months after the acute phase of their infection, with fatigue, pain,  
61 respiratory and cardiovascular symptoms, and mental health and cognitive disturbances being  
62 among the problems frequently described under the term “post-acute COVID-19 syndrome”;<sup>10</sup>  
63 however, epidemiological characterisation of such sequelae remains immature. Small descriptive  
64 studies of COVID-19 survivors have been suggestive of high incidence of a range of outcomes  
65 including respiratory, cardiovascular, and mental-health related, but firm conclusions are difficult  
66 due to lack of comparison groups.<sup>11,12</sup> There remains limited evidence about post-COVID sequelae  
67 across the full range of health outcomes. One recent study of US Department of Veterans Affairs  
68 (VA) data examined a wide range of diagnoses, prescriptions and laboratory abnormalities among  
69 30-day survivors of COVID-19, showing excess risks of several health outcomes in the 6 months  
70 following infection, compared with the general VA population.<sup>13</sup> Whether these findings generalise  
71 to the entire US population or other settings remains unclear. Another US study limited to people  
72 aged <65 years also found excess risks of a range of clinical outcomes ascertained from health  
73 insurance data among people with a record of SARS-CoV-2 infection.<sup>14</sup> A UK study of routinely-  
74 collected primary care and hospitalisation data described raised rates of all-cause hospital admission  
75 and death among patients discharged following a COVID-19 hospitalisation; the authors also noted  
76 raised risks of adverse respiratory and cardiovascular sequelae among the selected outcomes  
77 investigated.<sup>15</sup> Only a general population comparator was used, making it difficult to disentangle  
78 risks specific to COVID-19 from those associated with hospitalisation more generally; furthermore, a  
79 hospitalised cohort is likely to have been more prone to health problems at the outset than the  
80 general population comparator group.

81 To strengthen the evidence base in this important emerging area, we therefore aimed to investigate  
82 the incidence of subsequent hospital admission and death, both overall and from a wide range of  
83 specific causes, following a COVID-19 hospitalisation in England. We aimed to compare post-COVID  
84 risks with two separate comparison groups: (i) the general population, and (ii) people hospitalised  
85 for influenza prior to the current pandemic.

86

87

88

## 89 **Methods**

### 90 *Study design and study population*

91 A cohort study was carried out within the OpenSAFELY platform, which has been described  
92 previously.<sup>6</sup> We used routinely-collected electronic data from primary care practices using TPP  
93 SystmOne software, covering approximately 40% of the population in England, linked at the  
94 individual patient level to NHS Secondary Uses Service (SUS) data on hospitalisations, and Office of  
95 National Statistics death registration data (from 2019 onwards). We selected all individuals  
96 discharged between 1<sup>st</sup> February and 30<sup>th</sup> December 2020 from a hospitalisation that lasted >1 day  
97 and where COVID-19 was coded as the primary diagnosis (based on the International Classification  
98 of Diseases (ICD)-10 codes U07.1 “COVID-19 - virus identified” and U07.2 “COVID-19 - virus not  
99 identified”) and who were alive and under follow-up one week after discharge (to avoid a focus on  
100 hospital transfers and immediate readmissions/deaths). We excluded a small number of people with  
101 missing age, sex, or index of multiple deprivation, which are likely to indicate poor data quality. Two  
102 comparison groups were also selected: (i) people under follow-up in the general population in 2019,  
103 individually matched 5:1 to the COVID-19 group on age (within 3 years), sex, Sustainability and  
104 Transformation Plans (STP, a geographical area used as in NHS administration, of which there were  
105 32 in our data), and calendar month (e.g. a patient discharged from a COVID-19 hospitalisation in  
106 April 2020 was matched to 5 individuals of the same age, sex and STP who were under follow-up in  
107 general practice on 1<sup>st</sup> April 2019); (ii) all individuals discharged from hospital in 2017-2019 where  
108 influenza was coded as the primary reason for hospitalisation and who were alive and under follow-  
109 up one week after discharge.

110

### 111 *Outcomes and covariates*

112 The outcomes were (i) time to first hospitalisation or death (composite outcome); (ii) all-cause  
113 mortality; and (iii) time to first cause-specific hospitalisation or death. Hospitalisations were  
114 identified from linked SUS data. All-cause mortality was identified using date of death in the primary  
115 care record so that deaths before 2019 (in the influenza group) could be included (as linked ONS  
116 data were not available prior to 2019); concordance of death dates between primary care and linked  
117 ONS data has been shown to be high.<sup>16</sup> Cause-specific outcomes were categorised based on ICD-10  
118 codes into infections (ICD-10 codes beginning with “A”), cancers except non-melanoma skin cancer  
119 (C, except C44), endocrine/nutritional/metabolic (E), mental health and cognitive (F, G30 and X60-  
120 84), nervous system (G, except G30), circulatory (I), COVID-19/influenza/pneumonia/other lower  
121 respiratory tract infections (J09-22, U07.1/2), other respiratory (J23-99), digestive (K),  
122 musculoskeletal (M), genitourinary (N), and external causes (S-Y, except X60-84). For each of these,  
123 the outcome was time to the earliest of hospitalisation with the relevant outcome listed as primary  
124 diagnosis, or death with the relevant outcome listed as the underlying cause on the death  
125 certificate.<sup>17</sup> The influenza control group was restricted to those discharged in 2019 for analyses of  
126 these cause-specific outcomes, because we did not have linked death registration data (and thus  
127 cause of death) for earlier years.

128 Other covariates considered in the analysis were factors that might be associated with both risk of  
129 severe COVID-19 and subsequent outcomes, namely age, sex, ethnicity, obesity, smoking status,  
130 index of multiple deprivation quintile (derived from the patient’s postcode at lower super output  
131 area level), and comorbidities considered potential risk factors for severe COVID-19 outcomes (see  
132 Table 1 and footnotes for full specification of covariate categories and comorbidities).

133 Information on all covariates was obtained by searching TPP SystmOne records for specific coded  
134 data, based on a subset of SNOMED-CT mapped to Read version 3 codes. Covariates were identified  
135 using data prior to the patient’s hospital admission date (for the COVID-19 and influenza groups) or  
136 the index date (for the matched control group, i.e. 1<sup>st</sup> day of the matched calendar month in 2019).  
137 For the COVID-19 and influenza hospitalised groups, primary care data on ethnicity was

138 supplemented with information from the hospitalisation record, to improve completeness. All  
139 codelists, along with detailed information on their compilation are available at  
140 <https://codelists.opensafely.org> for inspection and re-use by the wider research community.

141

#### 142 *Statistical analysis*

143 Follow-up began on the 8<sup>th</sup> day after hospital discharge for the COVID-19 and influenza groups, and  
144 on the 1<sup>st</sup> of the same calendar month in 2019, for the general population control group. Follow-up  
145 ended at the first occurrence of the analysis-specific outcome, or the earliest relevant censoring date  
146 for data availability/coverage for the outcome being analysed; the control groups were additionally  
147 censored after the maximum follow-up time of the COVID-19 group (315 days). For outcomes  
148 involving hospital admissions the administrative censoring date (for SUS data) was 30<sup>th</sup> December  
149 2020; for outcomes involving cause of death, the administrative censoring date (for ONS mortality  
150 data) was 11<sup>th</sup> March 2021; for the all-cause death outcome which was ascertained in primary care  
151 data, patients were censored at date of deregistration if they had left the TPP general practice  
152 network. Cumulative incidence of the composite hospitalisation/death outcome and all-cause  
153 mortality were calculated using Kaplan-Meier methods. Hazard ratios comparing COVID-19 and  
154 controls were estimated using Cox regression models. Separate models were fitted for the  
155 comparisons with matched 2019 general population controls (models stratified by matched set), and  
156 with influenza controls (models adjusted for age, sex, STP and calendar month). The additional  
157 covariates noted above were then added to the models. People with missing data on ethnicity, body  
158 mass index or smoking were excluded from models that used these variables (“complete case  
159 analysis”, which is valid under the assumption that missingness is conditionally independent of the  
160 outcome);<sup>18</sup> imputation was not used because these variables were thought to be missing not at  
161 random in primary care (e.g. smokers more likely to have smoking status recorded). Cumulative  
162 incidence of cause-specific hospitalisation/death outcomes were calculated with deaths from other  
163 causes treated as a competing risk. Hazard ratios for these outcomes were then estimated from a  
164 Cox model targeting the cause-specific hazard, with deaths from competing risks censored.

165 The study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the  
166 LSHTM Ethics Board (ref 21863).

167

168

169

## 170 Results

171 24,673 individuals discharged after a COVID-19 hospitalisation were included, alongside 123,362  
172 matched controls from the 2019 general population, and 16,058 individuals discharged after  
173 influenza hospitalisation in 2017-19 (Appendix Figure A1-A2).

174 At entry, the COVID-19 group had similar age and sex distribution to the general population groups  
175 due to matching, but had younger median age and were more likely to be male than the influenza  
176 group (Table 1). Body mass index, smoking and ethnicity data were 93-99% complete in all groups,  
177 except that ethnicity was 25% missing in the matched control group (no hospital-based ethnicity  
178 records were available for this group). The COVID-19 group were more likely to be obese, non-White  
179 and less likely to be current smokers than both comparison groups. Pre-existing comorbidities were  
180 more common in both COVID-19 and influenza-discharged patients than general population  
181 controls. COVID-19 patients had longer median duration of hospital stay and were more likely to  
182 have received critical care during their admission than influenza patients.

183 Numbers of outcome events are shown in Appendix Table A1. Cumulative incidence of subsequent  
184 hospital admission or death after study entry in the COVID-19 group was higher than in general  
185 population controls, but similar to that in the influenza group (cumulative incidence at 6 months =  
186 34.8, 15.2 and 37.8% in the three groups respectively; fully adjusted HR = 2.23, 2.14-2.31 for COVID-  
187 19 vs general population; 0.94, 0.91-0.98 for COVID-19 vs influenza, Figures 1a, 2). Cumulative all-  
188 cause mortality was higher in the COVID-19 group than both the general population and influenza  
189 groups (7.5, 1.4 and 4.9% at 6 months in the three groups respectively; fully adjusted HR = 4.97,  
190 4.58-5.40 for COVID-19 vs general population; 1.73, 1.60-1.87 for COVID vs influenza, Figures 1b, 2).  
191 To further explore this, causes of death were examined (appendix Table A2). A substantial  
192 proportion of deaths in the COVID-19 group had COVID-19 listed as the underlying cause (500/2022,  
193 24.7%), while in the influenza group  $\leq 5$  deaths were coded with influenza as the underlying cause.

194 Cumulative incidences of cause-specific hospital admissions or deaths are shown in Figure 3. After  
195 adjustment for matching factors and other covariates, risks of all cause-specific outcomes were  
196 substantially higher in COVID-19 groups than general population controls (Figure 4). Compared with  
197 influenza patients, people in the COVID-19 group had similar or lower risk of admission or death  
198 from most causes, but higher risks of admission/death from COVID-19/influenza/lower respiratory  
199 tract infection (LRTI, adjusted HR 1.37, 1.22-1.54); in the post-COVID-19 group these outcomes were  
200 dominated by codes for COVID-19 itself (515/1122 [46%] of hospitalisations and 342/368 [93%] of  
201 deaths) and pneumonia (461/1122 [41%] of hospitalisations). The COVID-19 group also had higher  
202 risks than the influenza group for mental health or cognitive outcomes (adjusted HR 1.36, 1.01-1.83).  
203 This was further explored in a post-hoc analysis of specific outcomes within the mental health and  
204 cognitive category (Table 2). Raised risks in the COVID-19 group appeared to be driven by dementia  
205 hospitalisations/deaths (age/sex-adjusted HR 2.32, 1.48-3.64), particularly among those with pre-  
206 existing dementia at baseline (HR 2.47, 1.37-4.44) and/or resident in care homes (HR 2.53, 0.99-  
207 6.41). Of note, 129/161 dementia outcome events (80.1%) were deaths (rather than  
208 hospitalisations). Higher rates of hospitalisations/deaths due to mood disorders, and  
209 neurotic/stress-related/somatoform disorders were also observed in COVID-19 patients, but  
210 confidence intervals were too wide to be conclusive.

## 211 Discussion

### 212 *Key findings*

213 Patients discharged from a COVID-19 hospitalisation had more than double the risk of hospitalisation  
214 or death, and a 5-fold higher risk of all-cause mortality than controls from the general population,  
215 after adjusting for baseline personal and clinical characteristics. Risks were higher for all categories  
216 of disease-specific hospital admissions/deaths after a COVID-19 hospitalisation than in general  
217 population controls. Most outcomes were similar between people discharged from a COVID-19  
218 hospitalisation, and people discharged from an influenza hospitalisation in 2017-19, but the COVID-  
219 19 group had higher subsequent all-cause mortality; higher rates of respiratory infection admissions  
220 and deaths (predominantly COVID-19), and more adverse mental health and cognitive outcomes  
221 (particularly deaths attributed to dementia among people with pre-existing dementia) compared  
222 with the influenza group.

223

### 224 *Findings in context of literature and explanations*

225 A recent study of VA data on US veterans examined a wide range of diagnostic and other outcomes  
226 in 30-day COVID-19 survivors, compared with the general VA population.<sup>13</sup> Among veterans where  
227 COVID-19 had led to a hospitalisation, hazard ratios of every category of outcome were raised. This  
228 concurs with findings from our study, despite different characteristics of the VA population. In the  
229 UK, an earlier study found an 8-fold higher risk of death in post-acute COVID-19 patients compared  
230 with general population controls, and raised risks of respiratory disease, diabetes and cardiovascular  
231 disease.<sup>15</sup> Interestingly, recent data from Denmark suggest limited post-acute complications  
232 following non-hospitalised COVID-19;<sup>19</sup> this is in contrast to a recent study using US health insurance  
233 data which found raised risks of a range of outcomes among a relatively young cohort with mostly  
234 (92%) non-hospitalised COVID-19 disease, compared with both the general population and people  
235 with a record of other viral lower respiratory tract infections.<sup>14</sup>

236 Our data showed that COVID-19 hospitalised patients were more likely to have baseline  
237 comorbidities than general population controls, reflecting known associations between  
238 comorbidities and risks of severe COVID-19 outcomes.<sup>6</sup> Differences in outcomes between  
239 hospitalised patients and general population controls might therefore reflect baseline differences  
240 not fully captured in our adjustment models, and might also reflect a generic adverse effect of  
241 hospitalisation.<sup>20</sup> This is supported by the more similar risks we observed when COVID-19 survivors  
242 were compared with people who had experienced influenza hospitalisation. However, all-cause  
243 mortality was substantially higher after COVID-19 compared with influenza. A quarter of deaths after  
244 a COVID-19 hospitalisation had COVID-19 listed as the underlying cause, but it is not clear from our  
245 data whether patients experienced specific complications after hospital discharge that were then  
246 attributed to COVID-19.

247 Our analysis of cause-specific outcomes also suggested a disproportionate rate of dementia deaths  
248 post-COVID-19, particularly among those with pre-existing dementia. Cognitive decline after  
249 hospitalisation and critical illness have been previously described,<sup>21,22</sup> acute COVID-19 and  
250 associated hospital admission, social isolation, and medications may have accelerated progression of  
251 patients' dementia; it is unclear whether post-discharge care was adequate for this vulnerable  
252 group. However, it is possible that deaths where the underlying cause was recorded as dementia  
253 may have been due to progression of underlying health problems following an acute illness as well  
254 as difficulty in managing these due to dementia. Due to small numbers, we could not confirm  
255 whether higher rates of mood disorders and neurotic/stress-related/somatoform disorders after  
256 COVID-19 compared with influenza were due to chance, but a number of previous studies outside  
257 the pandemic context have found that critical illness is associated with raised risks of depression,  
258 anxiety and post-traumatic stress.<sup>23-25</sup> It will be important to continue to monitor these outcomes as  
259 more follow-up accumulates.

## 260 *Strengths and Limitations*

261 We identified COVID-19 hospitalisations from a base population covering around 40% of the  
262 population of England, giving us high statistical power. We examined a broad range of  
263 hospitalisation and mortality outcomes, and were able to describe and adjust for a wide range of  
264 personal and clinical characteristics using rich primary care data.

265  
266 However, our study has some limitations. We relied on ICD-10 codes entered as the primary reason  
267 for hospitalisation or underlying cause of death to define our cause-specific outcomes, but these  
268 fields may not have been used consistently.<sup>26</sup> In particular, there might have been a tendency for  
269 clinicians aware of a recent COVID-19 hospitalisation to code COVID-19 for a range of clinical  
270 complications, masking more specific sequelae. Outcomes were classified in broad categories to  
271 obtain an overview of post-COVID-19 disease patterns; more granular disease categories would be  
272 of future interest but will require more follow-up to maintain statistical power. Our main  
273 comparisons may have been affected by time-related factors. We compared post-COVID patients in  
274 2020 with controls from 2019 and earlier; consultations for non-COVID-19 conditions in 2020 are  
275 known to have been subdued in the general population,<sup>27</sup> perhaps due to lockdown, or public  
276 reluctance to seek care, potentially affecting comparison with earlier years. On the other hand,  
277 patients with recent a COVID-19 hospitalisation may assume immunity from reinfection and be less  
278 reticent in seeking care than the general population. The comparison with influenza may also have  
279 been affected by seasonality, since the first wave of COVID-19 in England happened outside the  
280 typical influenza season. Lack of overlap in the data meant that we could not incorporate seasonal  
281 adjustment into our statistical models for this comparison; any confounding by seasonality is likely to  
282 have led to underestimation of hazard ratios comparing COVID-19 and influenza patients, since cases  
283 of the former were under-represented in the winter months (which typically confer higher health  
284 risks). We did not have detailed data on disease severity, though descriptive data showed that  
285 COVID-19 patients tended to have longer hospital stays and more critical care than those  
286 hospitalised for influenza. Finally, data were unavailable on new/emerging COVID-19 variants during  
287 the study period.

288

## 289 *Conclusions*

290 Patients surviving a COVID-19 hospitalisation were at substantially higher risk than the general  
291 population for a range of subsequent adverse outcomes over a period of up to 10 months' follow-up  
292 included in this study. Risks for most outcomes were broadly comparable to those experienced by  
293 influenza hospitalisation survivors prior to the pandemic, but in the period following hospital  
294 discharge COVID-19 patients had higher risks of all-cause mortality, readmission or death attributed  
295 to their initial infection, and adverse mental health and cognitive outcomes; in particular, among  
296 people with pre-existing dementia, we observed an excess of deaths where dementia was recorded  
297 as the underlying cause. These findings suggest a need for services to support and closely monitor  
298 people following discharge from hospital with COVID-19.

299

300

301

## 302 **Contributors**

303 KB, CTR, WJH led the study design. GH led on platform support. KB did the analysis and wrote the  
304 first draft. BG conceived the OpenSAFELY platform and the approach. BG and LS lead the project  
305 overall and are guarantors. SB led on software development. AM led on information governance.  
306 Other contributions were – data curation - CB, JP, JC, SH, SB, DE, PI and CEM; disease category  
307 conceptualisation and codelists - KB CTR BM CB JC CEM AJW HIM IJD HJC JP; statistical analysis code:  
308 KB, EW; ethical approvals - HJC EW LS BG; software - SB, DE, PI, AJW, WJH, CEM, CB, FH, JC; writing  
309 (reviewing and editing) - KB, CTR, CWG, LT, BM, AS, AM, RME, CEM, IJD, SJWE, LS, BG. All authors  
310 were involved in design and conceptual development and reviewed and approved the final  
311 manuscript.

312

## 313 **Information Governance and Ethics**

314 NHS England is the data controller; TPP is the data processor; and the key researchers on  
315 OpenSAFELY are acting on behalf of NHS England. OpenSAFELY is hosted within the TPP environment  
316 which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit  
317 compliant;<sup>28,29</sup> patient data are pseudonymised for analysis and linkage using industry standard  
318 cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto  
319 OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection,  
320 restricted to a small group of researchers who hold contracts with NHS England and only access the  
321 platform to initiate database queries and statistical models. All database activity is logged. No  
322 patient-level data leave the platform; only aggregate statistical outputs leave the platform  
323 environment following best practice for anonymisation of results such as statistical disclosure  
324 control for low cell counts.<sup>30</sup> The OpenSAFELY platform adheres to the data protection principles of  
325 the UK Data Protection Act 2018 and the EU General Data Protection Regulation (GDPR) 2016. In  
326 March 2020, the Secretary of State for Health and Social Care used powers under the UK Health  
327 Service (Control of Patient Information) Regulations 2002 (COPI) to require organisations to process  
328 confidential patient information for the purposes of protecting public health, providing healthcare  
329 services to the public and monitoring and managing the COVID-19 outbreak and incidents of  
330 exposure.<sup>31</sup> Taken together, these provide the legal bases to link patient datasets on the  
331 OpenSAFELY platform. The study was approved by the Health Research Authority (REC reference  
332 20/LO/0651) and by the LSHTM Ethics Board (ref 21863).

333

## 334 **Declaration of interests**

335 This work was jointly funded by UKRI, NIHR and Asthma UK-BLF [COV0076; MR/V015737/] and the  
336 Longitudinal Health and Wellbeing strand of the National Core Studies programme. The OpenSAFELY  
337 data science platform is funded by the Wellcome Trust. TPP provided technical expertise and  
338 infrastructure within their data centre *pro bono* in the context of a national emergency. BG has  
339 received research funding from the Laura and John Arnold Foundation, the NHS National Institute  
340 for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical  
341 Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and  
342 Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the  
343 Health Foundation, the World Health Organisation, UKRI, Asthma UK, the British Lung Foundation,  
344 and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he also  
345 receives personal income from speaking and writing for lay audiences on the misuse of science. LS  
346 reports grants from Wellcome, MRC, NIHR, UKRI, British Council, GSK, British Heart Foundation, and  
347 Diabetes UK outside this work. KB holds a Senior Research Fellowship from Wellcome  
348 (220283/Z/20/Z). CWG is supported by a Wellcome Intermediate Clinical Fellowship  
349 (201440/Z/16/Z). HIM is funded by the National Institute for Health Research (NIHR) Health  
350 Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM.  
351 EW holds grants from MRC. ID holds grants from NIHR and GSK. HF holds a UKRI fellowship. RME is  
352 funded by HDR UK (grant: MR/S003975/1) and MRC (grant: MC\_PC 19065). The views expressed are

353 those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or  
354 the Department of Health and Social Care. Funders had no role in the study design, collection,  
355 analysis, and interpretation of data; in the writing of the report; and in the decision to submit the  
356 article for publication.

357

358

### 359 **Open access statement**

360 This research was funded in whole or in part by the Wellcome Trust. For the purpose of Open  
361 Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript  
362 (AAM) version arising from this submission.

363

### 364 **Data availability statement**

365 All data were linked, stored and analysed securely within the OpenSAFELY platform  
366 <https://opensafely.org/>. Data include pseudonymized data such as coded diagnoses, medications  
367 and physiological parameters. No free text data are included. All code is shared openly for review  
368 and re-use under MIT open license ([https://github.com/opensafely/post-admission-admissions-  
369 research](https://github.com/opensafely/post-admission-admissions-research)). Detailed pseudonymised patient data is potentially re-identifiable and therefore not  
370 shared. We rapidly delivered the OpenSAFELY data analysis platform without prior funding to deliver  
371 timely analyses on urgent research questions in the context of the global Covid-19 health  
372 emergency: now that the platform is established we are developing a formal process for external  
373 users to request access in collaboration with NHS England; updates on this process are available on  
374 OpenSAFELY.org.

375

376

### 377 **Patient and Public Involvement**

378 Patients were not formally involved in developing this specific study design that was developed  
379 rapidly in the context of a global health emergency. We have developed a publicly available website  
380 <https://opensafely.org/> through which we invite any patient or member of the public to contact us  
381 regarding this study or the broader OpenSAFELY project.

382

383

## 384 References

- 385 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021.  
386 <https://covid19.who.int> (accessed 12th May 2021).
- 387 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. *Ann Intern Med* 2020;  
388 **173**(5): 362-7. doi: 10.7326/M20-3012.
- 389 3. Prieto-Alhambra D, Balló E, Coma E, Mora N, Aragón M, Prats-Urbe A, Fina F, Benítez M,  
390 Guiriguat C, Fàbregas M, Medina-Peralta M, Duarte-Salles T. Filling the gaps in the characterization  
391 of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of  
392 118 150 cases diagnosed in outpatient settings in Spain. *Int J Epidemiol* 2020; **49**(6): 1930-9. doi:  
393 10.1093/ije/dyaa190.
- 394 4. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, Hayward A,  
395 Hemingway H, Horby P, Mehta N, Bengler J, Khunti K, Spiegelhalter D, Sheikh A, Valabhji J, Lyons RA,  
396 Robson J, Semple MG, Kee F, Johnson P, Jebb S, Williams T, Hippisley-Cox J. Living risk prediction  
397 algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults:  
398 national derivation and validation cohort study. *BMJ* 2020; **371**: m3731. doi: 10.1136/bmj.m3731.
- 399 5. Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, Eggo RM, Bhaskaran  
400 K, Wong AYS, Williamson EJ, Forbes H, Wing K, McDonald HI, Bates C, Bacon S, Walker AJ, Evans D,  
401 Inglesby P, Mehrkar A, Curtis HJ, DeVito NJ, Croker R, Drysdale H, Cockburn J, Parry J, Hester F,  
402 Harper S, Douglas IJ, Tomlinson L, Evans SJW, Grieve R, Harrison D, Rowan K, Khunti K, Chaturvedi N,  
403 Smeeth L, Goldacre B. Ethnic differences in SARS-CoV-2 infection and COVID-19-related  
404 hospitalisation, intensive care unit admission, and death in 17 million adults in England: an  
405 observational cohort study using the OpenSAFELY platform. *The Lancet* 2021; **397**(10286): 1711-24.  
406 doi: 10.1016/S0140-6736(21)00634-6.
- 407 6. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A,  
408 Evans D, Inglesby P. OpenSAFELY: factors associated with COVID-19 death in 17 million patients.  
409 *Nature* 2020: 1-11. doi: 10.1038/s41586-020-2521-4.
- 410 7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu  
411 X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients  
412 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.  
413 doi: 10.1016/S0140-6736(20)30566-3.
- 414 8. Navaratnam AV, Gray WK, Day J, Wendon J, Briggs TWR. Patient factors and temporal trends  
415 associated with COVID-19 in-hospital mortality in England: an observational study using  
416 administrative data. *The Lancet Respiratory Medicine* 2021; **9**(4): 397-406. doi: 10.1016/S2213-  
417 2600(20)30579-8.
- 418 9. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Qasim  
419 A, Martinez JPD, Rochwerg B, Lamontagne F, Han MA, Liu Q, Agarwal A, Agoritsas T, Chu DK, Couban  
420 R, Cusano E, Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ghadimi M, Heels-Ansdell D,  
421 Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, McLeod SL, Motaghi  
422 S, Murthy S, Mustafa RA, Neary JD, Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta  
423 A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO, Vernooij RW, Viteri-García A,  
424 Wang Y, Yao L, Ye Z, Guyatt GH, Brignardello-Petersen R. Drug treatments for covid-19: living  
425 systematic review and network meta-analysis. *BMJ* 2020; **370**: m2980. doi: 10.1136/bmj.m2980.
- 426 10. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig  
427 AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N,  
428 Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D,  
429 Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP,  
430 Landry DW, Wan EY. Post-acute COVID-19 syndrome. *Nat Med* 2021; **27**(4): 601-15. doi:  
431 10.1038/s41591-021-01283-z.
- 432 11. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri  
433 F, Rovere-Querini P, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of  
434 inflammatory and clinical predictors. *Brain Behav Immun* 2020; **89**: 594-600. doi:  
435 <https://doi.org/10.1016/j.bbi.2020.07.037>.
- 436 12. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W. Clinical sequelae of COVID-19 survivors in  
437 Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* 2021; **27**(1): 89-95. doi:  
438 <https://doi.org/10.1016/j.cmi.2020.09.023>.

- 439 13. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-  
440 19. *Nature* 2021. doi: 10.1038/s41586-021-03553-9.
- 441 14. Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, Lipsitch M,  
442 Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort  
443 study. *BMJ* 2021; **373**: n1098. doi: 10.1136/bmj.n1098.
- 444 15. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-  
445 covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*  
446 2021; **372**: n693. doi: 10.1136/bmj.n693.
- 447 16. Gallagher AM, Dedman D, Padmanabhan S, Leufkens HGM, de Vries F. The accuracy of date  
448 of death recording in the Clinical Practice Research Datalink GOLD database in England compared  
449 with the Office for National Statistics death registrations. *Pharmacoepidemiol Drug Saf* 2019; **28**(5):  
450 563-9. doi: 10.1002/pds.4747.
- 451 17. Office of National Statistics' Death Certification Advisory group. Guidance for doctors  
452 completing medical certificates of cause of death in England and Wales: Office of National Statistics,  
453 2020.
- 454 18. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case  
455 analysis for missing covariate values. *Stat Med* 2010; **29**(28): 2920-31. doi: 10.1002/sim.3944.
- 456 19. Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, Christiansen CF, Thomsen RW,  
457 Pottgård A. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital  
458 admission: a Danish population-based cohort study. *The Lancet Infectious Diseases*. doi:  
459 10.1016/S1473-3099(21)00211-5.
- 460 20. Krumholz HM. Post-hospital syndrome--an acquired, transient condition of generalized risk.  
461 *The New England journal of medicine* 2013; **368**(2): 100-2. doi: 10.1056/NEJMp1212324.
- 462 21. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE,  
463 Hughes CG, Vasilevskis EE, Shintani AK, Moons KG, Geevarghese SK, Canonico A, Hopkins RO,  
464 Bernard GR, Dittus RS, Ely EW. Long-Term Cognitive Impairment after Critical Illness. *N Engl J Med*  
465 2013; **369**(14): 1306-16. doi: 10.1056/NEJMoa1301372.
- 466 22. Wilson RS, Hebert LE, Scherr PA, Dong X, Leurgens SE, Evans DA. Cognitive decline after  
467 hospitalization in a community population of older persons. *Neurology* 2012; **78**(13): 950-6. doi:  
468 10.1212/WNL.0b013e31824d5894.
- 469 23. Nikayin S, Rabiee A, Hashem MD, Huang M, Bienvenu OJ, Turnbull AE, Needham DM. Anxiety  
470 symptoms in survivors of critical illness: a systematic review and meta-analysis. *Gen Hosp Psychiatry*  
471 2016; **43**: 23-9. doi: 10.1016/j.genhosppsych.2016.08.005.
- 472 24. Parker AM, Sricharoenchai T, Raparla S, Schneck KW, Bienvenu OJ, Needham DM.  
473 Posttraumatic stress disorder in critical illness survivors: a metaanalysis. *Crit Care Med* 2015; **43**(5):  
474 1121-9. doi: 10.1097/ccm.0000000000000882.
- 475 25. Rabiee A, Nikayin S, Hashem MD, Huang M, Dinglas VD, Bienvenu OJ, Turnbull AE, Needham  
476 DM. Depressive Symptoms After Critical Illness: A Systematic Review and Meta-Analysis. *Crit Care*  
477 *Med* 2016; **44**(9): 1744-53. doi: 10.1097/ccm.0000000000001811.
- 478 26. Amoretti MC, Lalumera E. COVID-19 as the underlying cause of death: disentangling facts  
479 and values. *History and Philosophy of the Life Sciences* 2021; **43**(1): 4. doi: 10.1007/s40656-020-  
480 00355-6.
- 481 27. Mansfield KE, Mathur R, Tazare J, Henderson AD, Mulick AR, Carreira H, Matthews AA,  
482 Bidulka P, Gayle A, Forbes H, Cook S, Wong AYS, Strongman H, Wing K, Warren-Gash C, Cadogan SL,  
483 Smeeth L, Hayes JF, Quint JK, McKee M, Langan SM. Indirect acute effects of the COVID-19 pandemic  
484 on physical and mental health in the UK: a population-based study. *The Lancet Digital Health* 2021;  
485 **3**(4): e217-e30. doi: 10.1016/S2589-7500(21)00017-0.
- 486 28. NHS Digital. BETA – Data Security Standards. 2020. [https://digital.nhs.uk/about-nhs-  
487 digital/our-work/nhs-digital-data-and-technology-standards/framework/beta---data-security-  
488 standards](https://digital.nhs.uk/about-nhs-digital/our-work/nhs-digital-data-and-technology-standards/framework/beta---data-security-standards) (accessed 6th August 2020).
- 489 29. NHS Digital. Data Security and Protection Toolkit. 2020. [https://digital.nhs.uk/data-and-  
490 information/looking-after-information/data-security-and-information-governance/data-security-  
491 and-protection-toolkit](https://digital.nhs.uk/data-and-information/looking-after-information/data-security-and-information-governance/data-security-and-protection-toolkit) (accessed 6th August 2020).
- 492 30. NHS Digital. ISB1523: Anonymisation Standard for Publishing Health and Social Care Data.  
493 2020. [https://digital.nhs.uk/data-and-information/information-standards/information-standards-  
494 and-data-collections-including-extractions/publications-and-notifications/standards-and-](https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-)

495 [collections/isb1523-anonymisation-standard-for-publishing-health-and-social-care-data](#) (accessed  
496 6th August 2020).

497 31. Secretary of State for Health - UK Government. Coronavirus (COVID-19): notification to  
498 organisations to share information. 2020.

499 [https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-](https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information)  
500 [controllers-to-share-information](#) (accessed 6th August 2020).

501

502

503

504 Table 1: Characteristics of patients hospitalised for COVID-19 and controls

		Hospitalised with COVID-19	Matched controls from 2019 general population	Hospitalised with influenza in 2017-19
<b>N (%)</b>		24673 (100.0)	123362 (100.0)	16058 (100.0)
<b>Age (yrs)</b>	18-39	2035 (8.2)	10175 (8.2)	2024 (12.6)
	40-49	2756 (11.2)	13780 (11.2)	1462 (9.1)
	50-59	4679 (19.0)	23395 (19.0)	2126 (13.2)
	60-69	4602 (18.7)	23010 (18.7)	2653 (16.5)
	70-79	5034 (20.4)	25170 (20.4)	3492 (21.7)
	80+	5567 (22.6)	27832 (22.6)	4301 (26.8)
	Median (IQR)	66 (53-78)	66 (53-78)	69 (52-80)
<b>Sex</b>	Male	13733 (55.7)	68662 (55.7)	7097 (44.2)
	Female	10940 (44.3)	54700 (44.3)	8961 (55.8)
<b>Body mass index (kg/m<sup>2</sup>)</b>	Not obese	12710 (51.5) [54.8]	82908 (67.2) [72.7]	10065 (62.7) [67.4]
N (% of total)	30-34.9 (Obese class I)	5860 (23.8) [25.3]	20985 (17.0) [18.4]	2853 (17.8) [19.1]
[% among non-missing]	35-39.9 (Obese class II)	2819 (11.4) [12.2]	7069 (5.7) [6.2]	1271 (7.9) [8.5]
	≥40 (Obese class III)	1789 (7.3) [7.7]	3015 (2.4) [2.6]	737 (4.6) [4.9]
	Missing	1495 (6.1)	9385 (7.6)	1132 (7.0)
<b>Smoking status</b>	Never	10350 (41.9) [42.2]	52145 (42.3) [43.0]	5711 (35.6) [35.8]
N (% of total)	Former	12498 (50.7) [51.0]	52426 (42.5) [43.2]	7346 (45.7) [46.1]
[% among non-missing]	Current	1663 (6.7) [6.8]	16699 (13.5) [13.8]	2874 (17.9) [18.0]
	Missing	162 (0.7)	2092 (1.7)	127 (0.8)
<b>Ethnicity</b>	White	19061 (77.3) [78.3]	80923 (65.6) [87.7]	14035 (87.4) [88.5]
N (% of total)	Mixed	313 (1.3) [1.3]	821 (0.7) [0.9]	121 (0.8) [0.8]
[% among non-missing]	South Asian	3457 (14.0) [14.2]	6727 (5.5) [7.3]	1242 (7.7) [7.8]
	Black	920 (3.7) [3.8]	2225 (1.8) [2.4]	251 (1.6) [1.6]
	Other	590 (2.4) [2.4]	1572 (1.3) [1.7]	211 (1.3) [1.3]
	Missing	332 (1.3)	31094 (25.2)	198 (1.2)
<b>Index of Multiple Deprivation</b>	1 (least deprived)	4622 (18.7)	25428 (20.6)	3282 (20.4)
	2	4743 (19.2)	25259 (20.5)	3251 (20.2)
	3	4678 (19.0)	23503 (19.1)	3272 (20.4)
	4	5183 (21.0)	24222 (19.6)	3133 (19.5)
	5 (most deprived)	5447 (22.1)	24950 (20.2)	3120 (19.4)
<b>Care home resident</b>	Yes	1197 (4.9)	1650 (1.3)	391 (2.4)
<b>Length of hospital stay</b>	Median (IQR)	7 (3-13)	-	4 (2-9)
<b>Any critical care</b>	Yes	2659 (10.8)	-	18 (0.1)
<b>Comorbidities</b>				
Hypertension		12132 (49.2)	48565 (39.4)	7550 (47.0)
Chronic respiratory disease		3841 (15.6)	9664 (7.8)	3588 (22.3)
Asthma	With no oral steroid use	3741 (15.2)	14364 (11.6)	2872 (17.9)
	With oral steroid use	1334 (5.4)	2375 (1.9)	1210 (7.5)
Chronic heart disease		5540 (22.5)	18285 (14.8)	3934 (24.5)
Diabetes	With HbA1c<58 mmol/mol	4727 (19.2)	14855 (12.0)	2443 (15.2)
	With HbA1c≥58 mmol/mol	3124 (12.7)	5567 (4.5)	1426 (8.9)
	With no recent HbA1c measure	402 (1.6)	1133 (0.9)	218 (1.4)
Cancer (non-haematological)	Diagnosed < 1 year ago	401 (1.6)	1044 (0.8)	316 (2.0)
	Diagnosed 1-4.9 years ago	708 (2.9)	2959 (2.4)	539 (3.4)
	Diagnosed ≥5 years ago	1622 (6.6)	7353 (6.0)	1167 (7.3)
Haematological malignancy	Diagnosed < 1 year ago	70 (0.3)	123 (0.1)	110 (0.7)
	Diagnosed 1-4.9 years ago	167 (0.7)	362 (0.3)	239 (1.5)
	Diagnosed ≥5 years ago	252 (1.0)	694 (0.6)	295 (1.8)
Reduced kidney function	Estimated GFR 30-60	4502 (18.2)	17986 (14.6)	3299 (20.5)
	Estimated GFR 15-<30	481 (1.9)	1313 (1.1)	350 (2.2)
	Estimated GFR <15 or dialysis	443 (1.8)	353 (0.3)	342 (2.1)
Chronic liver disease		414 (1.7)	901 (0.7)	222 (1.4)
Dementia		1677 (6.8)	4409 (3.6)	1198 (7.5)
Stroke		1835 (7.4)	4275 (3.5)	1057 (6.6)
Other neurological disease		861 (3.5)	1817 (1.5)	574 (3.6)
Organ transplant		173 (0.7)	168 (0.1)	189 (1.2)
Asplenia		99 (0.4)	242 (0.2)	78 (0.5)
Rheum arthritis/ lupus /psoriasis		2132 (8.6)	7717 (6.3)	1408 (8.8)
Other immunosuppressive disease		76 (0.3)	311 (0.3)	108 (0.7)

505 Note: Diabetes HbA1c category was determined according to the most recent glycated haemoglobin (HbA1c) recorded in the 15 months  
506 prior to the index date; other neurological disease was defined as motor neurone disease, myasthenia gravis, multiple sclerosis, Parkinson's  
507 disease, cerebral palsy, quadriplegia or hemiplegia, and progressive cerebellar disease; asplenia included splenectomy or a spleen  
508 dysfunction, including sickle cell disease; other immunosuppressive conditions was defined as permanent immunodeficiency ever  
509 diagnosed, or aplastic anaemia or temporary immunodeficiency recorded within the last year.


510 *Table 2: Post-hoc analysis of specific hospitalisation/mortality outcomes within the mental health*  
 511 *and cognitive category*

	[events] rate per 1000 person-years (95% CI)		Age- and sex- adjusted hazard ratio for COVID-19 vs influenza groups (95% CI)
	COVID-19 group	Influenza group	
<b>Dementia (F00-F03, G30)</b>	[134] 14.74 (12.45-17.46)	[27] 5.20 (3.57-7.58)	2.32 (1.48-3.64)
<i>(among those with baseline dementia)</i>	[102] 168.07 (138.43-204.07)	[14] 59.72 (35.37-100.84)	2.47 (1.37-4.44)
<i>(among those with no baseline dementia)</i>	[32] 3.77 (2.67-5.33)	[13] 2.62 (1.52-4.52)	1.23 (0.63-2.42)
<i>(among those resident in a care home)</i>	[56] 127.78 (98.34-166.04)	[<=5] 55.14 (22.95-132.47)	2.53 (0.99-6.41)
<i>(among those not resident in a care home)</i>	[78] 9.02 (7.22-11.26)	[22] 4.31 (2.84-6.55)	1.80 (1.08-2.98)
<b>Delirium (F05)</b>	[77] 8.47 (6.78-10.59)	[28] 5.39 (3.72-7.81)	1.10 (0.70-1.72)
<b>Schizophrenia/schizotypal/delusional disorders (F20-29)</b>	[<=5] 0.22 (0.06-0.88)	[<=5] 0.77 (0.29-2.05)	0.20 (0.03-1.12)
<b>Mood disorders (F30-39)</b>	[19] 2.09 (1.33-3.28)	[<=5] 0.77 (0.29-2.05)	1.61 (0.54-4.79)
<b>Neurotic/stress-related/somatoform disorders (F40-48)</b>	[13] 1.43 (0.83-2.46)	[<=5] 0.58 (0.19-1.79)	2.59 (0.71-9.52)
<b>All except dementia (F05-F99)</b>	[114] 12.54 (10.44-15.07)	[41] 7.90 (5.82-10.73)	1.12 (0.77-1.62)

512


513 *Figure 1: Cumulative incidence of admission or death (composite outcome), and all-cause mortality in*  
514 *patients discharged from COVID-19 hospital admissions, influenza hospital admissions, and in*  
515 *matched general population controls*

516 (a) *Composite outcome of hospitalisation or death*



517

518 (b) *All-cause mortality*




519

520

521

522 *Figure 2: Hazard ratios comparing exposed (prior COVID-19 hospitalisation) and controls for risk of*  
 523 *subsequent hospital admission or death (composite outcome) and all-cause mortality*



524

525 \*among those with complete data available (see Table 1)


526

527

528

529

530 *Figure 3: Cumulative incidence of cause-specific admission/death in patients discharged from COVID-*  
531 *19 hospital admissions, influenza hospital admissions, and in matched general population controls*




532

533 *Note: For each sub-panel in (c), the outcome was defined as the first hospitalisation or death record with an ICD-10 code in the given*  
534 *category listed as the primary reason for hospitalisation/underlying cause of death. Deaths from other causes were treated as competing*  
535 *risks. In the influenza group, only patients entering the study in 2019 were included in analysis of cause-specific outcomes, as linked cause of*  
536 *death data were only available from 2019 onwards.*

537

538 **Figure 4: Hazard ratios comparing exposed (prior COVID-19 hospitalisation) and controls for cause-**  
 539 **specific hospital admission/deaths, adjusted for age, sex and geography**




540

541 *\*In the influenza group, only patients entering the study in 2019 were included in analysis of cause-specific outcomes, as linked cause of*  
 542 *death data were only available from 2019 onwards.*

543 **Appendix**

544 Figure A1: Study flow chart




545

546

547

548 *Figure A2: Distribution of entry dates for those in the COVID-19 hospitalised group, and the influenza-*  
 549 *hospitalised and matched general population comparison groups*



550

551

552 *Table A1: Distribution of first outcomes (hospital admission or death) among included individuals*

	Hospitalised with COVID-19	Hospitalised with influenza in 2017-19*	Matched controls from 2019 general population
N	24673	16058 (6689 in 2019*)	123362
Any hospitalisation or death (composite outcome)	6499 (26.3)	7788 (48.5)	16681 (13.5)
Deaths	2022 (8.2)	1513 (9.4)	3904 (3.2)
<b>Cause-specific admissions/deaths (total [deaths])</b>			
Other infections (ICD-10 codes beginning A)	391 [<=5] (1.6)	255 [<=5] (3.8)	569 [6] (0.5)
Cancers (C, ex C44)	566 [174] (2.3)	355 [60] (5.3)	1478 [242] (1.2)
Endocrine, nutritional and metabolic (E)	218 [29] (0.9)	98 [13] (1.5)	361 [28] (0.3)
Mental health and cognitive (F/G30/X60-84)	248 [111] (1.0)	68 [26] (1.0)	356 [149] (0.3)
Nervous system (G, ex G30)	240 [84] (1.0)	116 [21] (1.7)	467 [98] (0.4)
Circulatory (I)	1039 [180] (4.2)	511 [56] (7.6)	2256 [300] (1.8)
COVID-19/Influenza/LRTI (J09-22, U07.1/2)	1490+ [368+] (6.0)	497 [18] (7.4)	1169 [55] (0.9)
Other respiratory (J23-99)	670 [98] (2.7)	526 [40] (7.9)	812 [100] (0.7)
Digestive (K)	751 [36] (3.0)	433 [11] (6.5)	2728 [26] (2.2)
Musculoskeletal (M)	408 [9] (1.7)	292 [7] (4.4)	1669 [14] (1.4)
Genitourinary (N)	573 [18] (2.3)	287 [<=5] (4.3)	1292 [28] (1.0)
External (S-Y, ex X60-84)	566 [<=5] (2.3)	301 [<=5] (4.5)	1476 [16] (1.2)

553

554

555

556

557

558

*Note: counts for cause specific deaths in square brackets are deaths which were not preceded by a previous hospitalisation in the same outcome category; these are the deaths that counted as outcome events in the cause-specific analysis, and not the total number of deaths from the given cause. \*In the influenza group, only patients entering the study in 2019 were included in analysis of cause-specific outcomes, as linked cause of death data were only available from 2019 onwards. \*In the COVID-19 group, 515/1122 (46%) hospitalisations in the COVID-19/Influenza/LRTI outcome category had COVID-19 codes (ICD-10 U07.1/2) and a further 461/1122 (41%) had pneumonia codes (J18) as the primary diagnosis; 342/368 deaths (93%) had COVID-19 as the underlying cause.*

559

560 *Table A2: Leading causes of death in COVID-19 and influenza groups*

	<b>COVID-19 group, N (%)</b> (2022 total deaths)		<b>Influenza group, N (%)</b> (558 total deaths*)
COVID-19	500 (25)	Cancer	150 (27)
Cancer	359 (18)	Circulatory diseases	112 (20)
Circulatory diseases	339 (17)	Other respiratory (ICD 10 J23-99)	101 (18)
Other respiratory (ICD 10 J23-99)	156 (8)	Mental health/cognitive	35 (6)
Mental health/cognitive	150 (7)	Nervous system (Influenza)	32 (6) ≤5 (<1%)

561 *\*Only 558/1513 deaths in the influenza group are included in this table as the remainder (pre-2019) did not have cause of*  
 562 *death data available (cause of death data were only available for 2019 onwards).*

563

564

565